OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition

Sandra D'Angelo, MD

Medical oncologist at Memorial Sloan Kettering Cancer Center, dedicated to advancing immunotherapy for the treatment of sarcoma. Her work focuses on evaluating the efficacy of emerging immunotherapeutic approaches and identifying biomarkers that predict patient response in these rare tumors, in close collaboration with basic scientists, cooperative research groups, and industry partners.

At MSK, she leads a sarcoma-focused translational research program in immunotherapy, where she systematically investigates innovative combination strategies, including, but not limited to, checkpoint inhibitors and adoptive T-cell therapies.

Herbert Loong, MBBS, PDipMDPath, MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO

Associate Professor (Clinical), Department of Clinical Oncology
Medical Director (Oncology), Phase 1 Clinical Trial Centre
The Chinese University of Hong Kong
Consultant (Honorary), Department of Clinical Oncology, Prince of Wales
Hospital, Hong Kong SAR, China

He trained at The University of Hong Kong, graduated with distinction in surgery, and further specialized in drug development through a fellowship at Princess Margaret Cancer Centre, focusing on experimental therapeutics. His clinical and academic work centers on thoracic oncology and sarcoma, with a particular emphasis on early-phase trials and innovative treatment strategies.

He is a Fellow of American Society of Clinical Oncology (FASCO, 2024) and recipient of multiple international awards. He co-founded regional initiatives such as APODDC and APCLC, and has held leadership roles within ASCO, International Association for the Study of Lung Cancer, and CTOS, contributing to global oncology collaboration, policy development, and advancement of clinical research.